Role of interleukin-35 in sublingual allergy immunotherapy

Autor: Shamji, MH, Layhadi, JA, Achkova, D, Kouser, L, Perera-Webb, A, Couto-Francisco, NC, Parkin, R, Matsuoka, T, Scadding, G, Ashton-Rickardt, PG, Durham, SR

Publikováno v: 1142.e4

BACKGROUND: Grass pollen-specific immunotherapy involves immunomodulation of allergen-specific T helper 2 cell (Th2) responses and induction of IL-10+ and/or TGF-β+CD4+CD25+ regulatory T cells (iTregs). IL-35+CD4+CD25+Foxp3- T (iTR35) cells have bee

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1032::9e1a84bbb3ac0764409ee19a6537f420
http://hdl.handle.net/10044/1/61503

Cromolyn sodium and masitinib combination inhibits fibroblast‐myofibroblast transition and exerts additive cell‐protective and antioxidant effects on a bleomycin‐induced in vitro fibrosis model.

Autor: Göksu, Azize Yasemin^1,2 (AUTHOR) yasemin.goksu@gmail.com, Dirol, Hulya³ (AUTHOR), Kocanci, Fatma Gonca⁴ (AUTHOR)

Publikováno v: Pharmacology Research & Perspectives. Oct2024, Vol. 12 Issue 5, p1-16. 16p.

Role of IL-35 in sublingual allergen immunotherapy.

Autor: Shamji MH; Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, and the MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, London, United Kingdom. Electronic address: m.shamji@imperial.ac.uk., Layhadi JA; Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, and the MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, London, United Kingdom., Achkova D; Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, and the MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, London, United Kingdom., Kouser L; Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, and the MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, London, United Kingdom., Perera-Webb A; Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, and the MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, London, United Kingdom., Couto-Francisco NC; Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, and the MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, London, United Kingdom., Parkin RV; Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, and the MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, London, United Kingdom., Matsuoka T; Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, and the MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, London, United Kingdom., Scadding G; Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, and the MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, London, United Kingdom., Ashton-Rickardt PG; Section of Immunobiology, Division of Immunology and Inflammation, Department of Medicine, Faculty of Medicine, Imperial College London, London, United Kingdom., Durham SR; Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, and the MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, London, United Kingdom.

Publikováno v: The Journal of allergy and clinical immunology [J Allergy Clin Immunol] 2019 Mar; Vol. 143 (3), pp. 1131-1142.e4. Date of Electronic Publication: 2018 Jul 25.

T-cell gene therapy for perforin deficiency corrects cytotoxicity defects and prevents hemophagocytic lymphohistiocytosis manifestations.

Autor: Ghosh S; Infection, Immunity, Inflammation, Molecular and Cellular Immunology Section, UCL Great Ormond Street Institute of Child Health, London, United Kingdom; Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Center of Child and Adolescent Health, Heinrich-Heine-University, Dusseldorf, Germany., Carmo M; Infection, Immunity, Inflammation, Molecular and Cellular Immunology Section, UCL Great Ormond Street Institute of Child Health, London, United Kingdom., Calero-Garcia M; Infection, Immunity, Inflammation, Molecular and Cellular Immunology Section, UCL Great Ormond Street Institute of Child Health, London, United Kingdom., Ricciardelli I; Infection, Immunity, Inflammation, Molecular and Cellular Immunology Section, UCL Great Ormond Street Institute of Child Health, London, United Kingdom., Bustamante Ogando JC; Infection, Immunity, Inflammation, Molecular and Cellular Immunology Section, UCL Great Ormond Street Institute of Child Health, London, United Kingdom., Blundell MP; Infection, Immunity, Inflammation, Molecular and Cellular Immunology Section, UCL Great Ormond Street Institute of Child Health, London, United Kingdom., Schambach A; Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany., Ashton-Rickardt PG; Section of Immunobiology, Division of Inflammation and Immunology, Department of Medicine, Faculty of Medicine, Imperial College, London, United Kingdom., Booth C; Infection, Immunity, Inflammation, Molecular and Cellular Immunology Section, UCL Great Ormond Street Institute of Child Health, London, United Kingdom., Ehl S; Center for Chronic Immunodeficiency, University Medical Center, University of Freiburg, Freiburg, Germany., Lehmberg K; Department of Paediatric Haematology and Oncology, Division of Paediatric Stem Cell Transplantation and Immunology, University Medical Centre Hamburg-Eppendorf, Hamburg-Eppendorf, Germany., Thrasher AJ; Infection, Immunity, Inflammation, Molecular and Cellular Immunology Section, UCL Great Ormond Street Institute of Child Health, London, United Kingdom., Gaspar HB; Infection, Immunity, Inflammation, Molecular and Cellular Immunology Section, UCL Great Ormond Street Institute of Child Health, London, United Kingdom. Electronic address: h.gaspar@ucl.ac.uk.

Publikováno v: The Journal of allergy and clinical immunology [J Allergy Clin Immunol] 2018 Sep; Vol. 142 (3), pp. 904-913.e3. Date of Electronic Publication: 2018 Jan 31.

C1q restrains autoimmunity and viral infection by regulating CD8 ⁺ T cell metabolism.

Autor: Ling GS; Faculty of Medicine, Imperial College London, London W12 ONN, UK., Crawford G; Faculty of Medicine, Imperial College London, London W12 ONN, UK., Buang N; Faculty of Medicine, Imperial College London, London W12 ONN, UK., Bartok I; Faculty of Medicine, Imperial College London, London W12 ONN, UK., Tian K; Faculty of Medicine, Imperial College London, London W12 ONN, UK., Thielens NM; University Grenoble Alpes, CEA, CNRS, IBS, F-38000 Grenoble, France., Bally I; University Grenoble Alpes, CEA, CNRS, IBS, F-38000 Grenoble, France., Harker JA; Faculty of Medicine, Imperial College London, London W12 ONN, UK., Ashton-Rickardt PG; Faculty of Medicine, Imperial College London, London W12 ONN, UK., Rutschmann S; Faculty of Medicine, Imperial College London, London W12 ONN, UK., Strid J; Faculty of Medicine, Imperial College London, London W12 ONN, UK., Botto M; Faculty of Medicine, Imperial College London, London W12 ONN, UK. m.botto@imperial.ac.uk.

Publikováno v: Science (New York, N.Y.) [Science] 2018 May 04; Vol. 360 (6388), pp. 558-563.